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Background: Helical Tomotherapy (HT) has unique capacities for the radiotherapy of large and complicated target
volumes. Next generation Dynamic Jaw/Dynamic Couch HT delivery promises faster treatments and reduced
exposure of organs at risk due to a reduced dose penumbra.
Methods: Three challenging clinical situations were chosen for comparison between Regular HT delivery with a
field width of 2.5 cm (Reg 2.5) and 5.0 cm (Reg 5.0) and DJDC delivery with a maximum field width of 5.0 cm
(DJDC 5.0): Hemithoracic Irradiation, Whole Abdominal Irradiation (WAI) and Total Marrow Irradiation (TMI). For each
setting, five CT data sets were chosen, and target coverage, conformity, integral dose, dose exposure of organs at
risk (OAR) and treatment time were calculated.
Results: Both Reg 5.0 and DJDC 5.0 achieved a substantial reduction in treatment time while maintaining similar
dose coverage. Treatment time could be reduced from 10:57 min to 3:42 min / 5:10 min (Reg 5.0 / DJDC 5.0) for
Hemithoracic Irradiation, from 18:03 min to 8:02 min / 8:03 min for WAI and to 18:25 min / 18:03 min for TMI. In
Hemithoracic Irradiation, OAR exposure was identical in all modalities. For WAI, Reg 2.5 resulted in lower exposure
of liver and bone. DJDC plans showed a small but significant increase of ∼ 1 Gy to the kidneys, the parotid glans
and the thyroid gland. While Reg 5.0 and DJDC were identical in terms of OAR exposure, integral dose was
substantially lower with DJDC, caused by a smaller dose penumbra.
Conclusions: Although not clinically available yet, next generation DJDC HT technique is efficient in improving the
treatment time while maintaining comparable plan quality.
Keywords: Dynamic jaw/dynamic couch, Helical tomotherapy, Large volumes, Hemithoracic irradiation, Whole
abdominal irradiation, Total marrow irradiationBackground
Helical Tomotherapy (HT) has proven to have unique
capacities for the radiotherapy treatment of large target
volumes [1,2]. Technical details of HT have been
described extensively before [3]. In brief, a HT unit with
its ring gantry forms a fusion of a linear accelerator and
a helical CT scanner [4]. The treatment beam can be
shaped into different beam widths depending on the
opening angle of the secondary collimator (jaws). In an* Correspondence: sonja.krause@med.uni-heidelberg.de
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reproduction in any medium, provided the orinverse treatment planning process, the MLC conform-
ation is optimised to obtain highly conformal radiation
doses to the target [5]. As the patient is moved through
the gantry, targets up to a length of 160 cm can be
treated in one treatment run. While HT can yield excel-
lent target coverage and sparing of organs at risk in the
treatment of very large volumes [6], it has often been
criticised because of long treatment times.
During the last years, other techniques of rotational
IMRT have evolved. As initially described by Otto [7], in
volumetric modulated arc therapy dose is delivered by a
modulated beam with a field size of up to 40 × 40 cm
using one or very few rotations. This technique offerstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of low or intermediate complexity [8]. Satisfactory cover-
age of complex volumes frequently needs more than one
rotation, and very large target extensions often demand
multiple isocenters that require additional patient setup
time.
With HT, the problem of field junctioning in large
targets has been solved by the helical superposition of
multiple beam rotations. However, treatment time is
still a crucial factor influencing treatment safety, as patient
motion and the subsequent risk of dose uncertainties
increases with treatment time. New HT developments
such as Dynamic Jaw/Dynamic Couch (DJDC) have the
potential to speed up treatment substantially: While in
current HT the field width (determined by the jaw open-
ing) as well as the couch speed remain constant once
chosen at the beginning of treatment planning, DJDC
allows for the dynamic adaptation of field width and
couch speed depending on target complexity. Thus, areas
with less complex target shapes can be treated fast and
with a broad field width without compromising OAR
sparing and target coverage in more critical localisations
[9,10]. In addition, dynamic opening of the jaws at the
start and end of the target reduces the craniocaudal dose
penumbra caused by a constant field width. Currently,
DJDC is still in development and not available for clinical
routine yet.
To put DJDC to the test, we chose three clinical settings
where the radiation oncologist is faced with the challenge
of treating very large and complex volumes in close prox-
imity to critical organs at risk. The first was the treatment
of one complete hemithorax after radical surgery for
Malignant Pleural Mesothelioma. Secondly, we investigated
Whole Abdominal Irradiation (WAI) after surgery for ovar-
ian cancer, and thirdly the treatment of the complete bone
marrow (Total Marrow Irradiation, TMI) as part of condi-
tioning regimens before stem cell transplantation.
The present planning study compares state-of-the-art
HT with 2.5 cm and 5.0 cm field width to DJDC and
characterises the benefits of future HT developments for
the treatment of three very large volumes: Hemithoracic
Irradiation, WAI and TMI.
Materials and methods
This plan comparison study consisted of 15 anonymised
clinical cases forming three groups: 5 patients with
Malignant Pleural Mesothelioma had obtained a hemi-
thoracic irradiation with HT and 5 patients had been
treated with a HT Whole Abdominal Irradiation (WAI)
for ovarian cancer FIGO IIIc. In preparation for a clin-
ical Total Marrow Irradiation (TMI) trial, the plans for
TMI were conducted on 5 planning CT scans of patients
that had obtained a craniospinal irradiation with a suit-
able CT scan length. For all settings, the original CTscans, and for hemithoracic irradiation and WAI also
the original structure sets were used to generate Reg 2.5,
Reg 5 and DJDC plans on the original data sets. All
plans were calculated and evaluated by the same two per-
sons to keep variations in planning procedure als low as
possible.
Hemithoracic irradiation
Two patients suffered from left-sided, three patients
from right-sided mesothelioma. All 5 patients had
obtained neoadjuvant chemotherapy with cisplatin and
pemetrexed and extrapleural pneumonectomy and had
been treated with regular HT Hemithoracic irradiation
using a field width of 2.5 cm (Reg 2.5), because in clin-
ical routine, a 5.0 cm field width resulted in larger ex-
posure of the neck as well as the left kidney or the liver.
Planning CT scans with 3.0 mm slices were used. The
PTV included the former pleural cavity and the surgical
scars with a security margin of 1.0 cm and had an aver-
age volume of 3199 ml. A median dose of 54.0 Gy in 27
fractions was prescribed to the PTV. Reg 2.5 plans were
compared to Reg 5.0 and DJDC 5.0 plans in terms of
treatment time, target coverage and exposure of organs
at risk (OAR). All HT modalities were planned on a fine
calculation grid with a pitch of 0.287. For Reg 2.5 and
Reg 5.0, the Intensity Modulation Factor (IMF; max-
imum leaf intensity divided by the average leaf intensity)
was increased gradually up to 2.4, while for DJDC an
IMF of 2.2-2.5 was reached. Of note, the IMF for DJDC
represents the value given during planning, not the ac-
tual IMF calculated by the planning system, as the re-
search version does not allow the specification of a
commissioned treatment machine and consecutively
does not permit a final dose calculation.
Whole abdominal irradiation
All 5 patients were treated for ovarian cancer stage
FIGO IIIc after resection of the ovaries and the periton-
eum including all macroscopic tumor lesions and adju-
vant platinum-based chemotherapy. The PTV consisted
of the complete peritoneal cavity with a security margin
of 1.5 cm (2.5 cm in craniocaudal direction). For HT
planning purposes, the PTV was subdivided in order to
control underdosage due to OAR sparing: Two PTVs
surrounded the left and right kidneys, one covered the
upper part of the abdomen close to the lung and the
fourth PTV covered the rest of the abdominal cavity.
Planning CT scans of 5.0 mm slice thickness were used.
A median dose of 30.0 Gy in 1.5 Gy fractions was pre-
scribed. Again, the Reg 2.5 plans used in clinical routine
were compared to Reg 5.0 and DJDC 5.0 plans. Both HT
plans had a pitch of 0.287; Reg 2.5 and Reg 5.0 plans
needed an IMF of 4.0 while DJDC planning resulted in
an IMF of 3.6 - 4.0.
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In preparation for clinical phase I TMI trial, planning
CT scans with 5 mm slice thickness of patients receiving
craniospinal irradiation were chosen for TMI planning
because of the suitable scan length. The CTV comprised
the complete bone marrow with the exception of the
mandible and maxillary bones for a better sparing of the
oral mucosa. For PTV construction, different security
margins were applied depending on localisation: For the
skull down to C2, no security margin was applied as the
fixation with a rigid mask ensures precise positioning,
on other locations, a security margin of 5 mm was
chosen. A median of 18 Gy in 9 fractions was prescribed
to the PTV. As for the other indications, Reg 2.5 was
compared to Reg 5.0 and DJDC 5.0. To account for the
large craniocaudal extension of the PTV, a pitch of 0.43
was chosen for HT plans; the IMF was increased up to
2.5 for all HT plans.Plan comparison and statistical analysis
Plan quality concerning the PTV was judged using D99
and D1 (dose to 99% and 1% of the target volume), CI95
(Conformity Index; total volume covered by the 95% iso-
dose divided by the volume of the PTV covered by the
95% isodose), UI (Uniformity Index; dose covering 5% of
the PTV divided by the dose covering 95% of the PTV)
and TV95% (PTV volume covered by 95% of the pre-
scribed dose divided by the PTV volume). Sparing of
organs at risk was judged by maximum and average dose
as well as integral dose (product of the total volume and
the mean dose to that volume).Figure 1 Average treatment times (sec) for Hemithoracic Irradiation,
(TMI) for the Reg. 2.5, Reg 5.0 (“regular” delivery with a 2.5 cm and 5
delivery with a 5.0 cm maximum field width) plans. In all three plan gr
compared to Reg 2.5 (* p < 005).For statistical analysis, a two-sided paired t-test was




Regular HT with 2.5 cm field width of all three types of
complex and very large target volumes took an average
of 10:57 min (Hemithoracic Irradiation), 18:03 min
(WAI) and 39:23 min (TMI). Using a field width of 5.0 cm
in regular delivery more than halved average treatment
time to 3:42 min for Hemithoracic Irradiation, 8:02 min for
WAI and 18:25 min for TMI. With DJDC technique,
Hemithoracic Irradiation took longer than with Reg 5.0
(5:01 min, not significant), while WAI and TMI treatments
were as fast as with Reg 5.0 (8:03 min and 19:01 min) (see
Figure 1). While treatment speed was comparable for
DJDC and Reg 5.0, the latter produced a larger craniocau-
dal dose penumbra and consecutively a higher integral
dose (see below).
Target coverage
Although for DJDC planning a maximum field width
twice as large as in regular delivery was permitted, dose
distribution in the target volumes remained on a similar
level (see Tables 1, 2, 3 and Figures 2, 3, 4). Target cover-
age as indicated by TV95% was almost identical in all
modalities for Hemithoracic Irradiation and TMI. For
WAI, a significantly better coverage could be attained
with Reg 2.5.
Target coverage in the chest wall dropped in all mo-
dalities in proximity to the lungs to a level of about 12Whole Abdominal Irradiation (WAI) and Total Marrow Irradiation
.0 field width) and DJDC 5.0 (Dynamic Jaw/Dynamic Couch
oups, DJDC 5.0 came up with significantly shorter treatment times
Table 1 Hemithoracic irradiation: plan characteristics for
Reg 2.5, Reg 5.0 (“regular” delivery with a 2.5 cm and 5.0
cm field width) and DJDC 5.0 (dynamic jaw/dynamic
couch delivery with a 5.0 cm maximum field width)
Reg 2.5 Reg 5.0 DJDC 5.0
PTV D99 (Gy) 48.6 ± 0.6 49.5 ± 1.0 48.7 ± 0.6
D1 (Gy) 56.0 ± 0.5 57.7 ± 1.3 55.9 ± 0.2
CI95 1.14 ± 0.08 1.19 ± 0.06 1.16 ± 0.05
UI 1.06 ± 0.03 1.09 ± 0.04 1.06 ± 0.00
TV95% 0.967 ± 0.015 0.975 ± 0.009 0.967 ± 0.004
liver mean (Gy) 20.1 ± 9.1 20.7 ± 9.4 19.9 ± 10.1
ipsilateral
kidney
mean (Gy) 8.8 ± 3.0 8.3 ± 2.9 8.4 ± 2.6
contralateral
kidney
mean (Gy) 4.0 ± 1.2 3.6 ± 0.9 3.3 ± 1.2
contralateral
lung
mean (Gy) 6.1 ± 0.6 6.2 ± 0.7 6.0 ± 1.0
spinal cord max (Gy) 35.0 ± 6.2 32.3 ± 0.9 34.1 ± 2.1
heart mean (Gy) 26.5 ± 4.8 26.9 ± 6.9 26.7 ± 5.3
esophagus mean (Gy) 32.0 ± 3.2 32.5 ± 1.2 31.5 ± 3.1
integral dose (Gy x l) 411.4 ± 24.5 513 ± 110.9 414.6 ± 31.3
No statistically significant differences could be detected in dose distribution in
the PTV and sparing of organs at risk.
Table 3 Total marrow irradiation: plan characteristics for
Reg 2.5, Reg 5.0 (“regular” delivery with a 2.5 cm and 5.0
cm field width) and DJDC 5.0 (dynamic jaw/dynamic
couch delivery with a 5.0 cm maximum field width)
Reg 2.5 Reg 5.0 DJDC 5.0
PTV D99 (Gy) 12.2 ± 0.6 11.9 ± 0.6 11.9 ± 0.3
D1 (Gy) 19.6 ± 0.3 20.1 ± 0.4 19.6 ± 0.3
CI95 1.30 ± 0.15 1.7 ± 0.23 1.47 ± 0.05
UI 1.27 ± 0.05 1.34 ± 0.08 1.31 ± 0.07
TV95% 0.781 ± 0.074 0.768 ± 0.037 0.768 ± 0.057
bladder mean (Gy) 6.8 ± 1.3 8.2 ± 1.1 8.0 ± 1.8
small bowel mean (Gy) 6.8 ± 1.2 8.2 ± 1.1 7.2 ± 1.0
D50 (Gy) 6.0 ± 0.9 8.1 ± 3.7 6.6 ± 1.0
esophagus mean (Gy) 6.7 ± 1.2 9.0 ± 0.5 7.2 ± 1.0
brain mean (Gy) 8.3 ± 0.6 8.1 ± 1.3 8.7 ± 1.6
D50 (Gy) 6.9 ± 0.8 7.2 ± 1.7 8.1 ± 0.3
liver mean (Gy) 7.6 ± 0.4 8.3 ± 0.5 8.5 ± 0.6
lenses mean (Gy) 2.4 ± 0.2 2.5 ± 0.3 2.7 ± 0.3
right lung mean (Gy) 8.0 ± 0.2 8.2 ± 0.3 8.1 ± 0.1
D50 (Gy) 6.2 ± 0.3 6.7 ± 0.3 6.6 ± 0.1
left lung mean (Gy) 8.0 ± 0.1 8.1 ± 0.3 8.1 ± 0.3
D50 (Gy) 6.3 ± 0.1 6.7 ± 0.3 6.6 ± 0.1
stomach mean (Gy) 5.2 ± 0.8 6.6 ± 1.1 5.9 ± 0.7
kidneys mean (Gy) 6.1 ± 0.6 6.0 ± 0.8 7.1 ± 0.8
parotid glands mean (Gy) 4.2 ± 0.8 4.2 ± 0.9 5.8 ± 1.2
thyroid gland mean (Gy) 4.2 ± 0.5 4.9 ± 0.5 5.1 ± 0.5
integral dose (Gy x l) 631.9 ± 143.4 724.5 ± 140.6 690.0 ± 122.3
Conformity was superior in Reg 2.5 compared to Reg 2.5 and DJDC 5.0 (bold
print). Reg 2.5 slightly outperformed DJDC 5.0 in terms of liver, kidney, parotid
gland and thyroid sparing and D50 to both lungs (bold print).
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width was used. In Figure 4, the equivalent lung sparing
and dose fall-off in the target is indicated by light
arrowheads.
Conformity was on the same level in all delivery
modes for Hemithoracic Irradiation and WAI. In the
TMI plans, having the largest and most complex target
volumes, conformity was slightly, yet significantly, worse
for Reg 5.0 and DJDC 5.0 as compared to Reg 2.5 (see
Table 3).Table 2 Whole abdominal irradiation: plan characteristics
for Reg 2.5, Reg 5.0 (“regular” delivery with a 2.5 cm and
5.0 cm field width) and DJDC 5.0 (dynamic jaw/dynamic
couch delivery with a 5.0 cm maximum field width)
Reg 2.5 Reg 5.0 DJDC 5.0
total PTV CI95 1.11 ± 0.08 1.13 ± 0.04 1.16 ± 0.03
TV95% 0.925 ± 0.013 0.887 ± 0.007 0.931 ± 0.022
right
kidney
mean (Gy) 11.9 ± 0.8 12.3 ± 1.1 13.0 ± 0.9
left kidney mean (Gy) 10.7 ± 0.8 11.7 ± 1.0 11.5 ± 0.8
bone mean (Gy) 10.8 ± 1.1 12.9 ± 1.0 11.7 ± 0.8
spinal cord max (Gy) 12.7 ± 2.7 12.5 ± 1.1 13.6 ± 2.7
heart mean (Gy) 9.5 ± 2.4 10.6 ± 2.7 10.5 ± 1.5
liver mean (Gy) 22.3 ± 0.9 23.5 ± 0.5 23.7 ± 0.9
integral
dose
(Gy x l) 369.3 ± 67.8 496.2 ± 92.3 382.9 ± 52.4
Target coverage and bone and liver sparing were significantly better with Reg
2.5 (bold print). Reg 5.0 resulted in a significantly higher integral dose than
Reg 2.5 and DJDC 5.0 (bold print).OAR sparing and integral dose
With the dynamic opening and closing of the secondary
collimator at the start and end of the target in DJDC
5.0 plans, a smaller craniocaudal dose penumbra com-
pared to Reg 2.5 and Reg 5.0 plans could be realised
(see Figures 5 and 6), allowing a better genital sparing
in WAI and a sparing of the neck and supraclavicular
area in Hemithoracic Irradiation. Consecutively, inte-
gral dose was significantly lower in WAI plans when
using DJDC 5.0 instead of Reg 2.5 or Reg 5.0. In
Hemithoracic Irradiation and TMI, the reduction of in-
tegral dose by DJDC compared to Reg 5.0 did not
reach statistical significance. In all settings, DJDC 5.0
resulted in a slightly higher integral dose than Reg 2.5
(not significant).
Consequentially, DJDC plans showed a tendency to
a higher exposure of organs at risk. In Hemithoracic
Irradiation, no significant increase could be detected,
with the cardinal organ at risk, the contralateral lung,
receiving 6.1 Gy (Reg 2.5) , 6.2 Gy (Reg 5.0) and 6.0 Gy
Figure 2 Hemithoracic Irradiation: Dose distributions for Reg 2.5 (“regular” delivery with a 2.5 cm field width; upper row) and DJDC
5.0 (Dynamic Jaw/Dynamic Couch delivery with a 5.0 cm maximum field width; lower row). Note the sparing of the liver in both
modalities (arrowheads) and the reduced craniocaudal dose penumbra in DJDC plans.
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differ significantly in the WAI plans except for a higher
bone exposure in Reg 5.0. Most notably, exposure of the
liver and both kidneys remained on the same level.
For TMI, mean dose exposure of brain, lenses and
lungs remained on a similar level in all delivery modes,
while bladder, small bowel and stomach experienced a
non-significant dose increase in Reg 5.0 and DJDC 5.0.
Kidneys, parotid glands and thyroid gland received a sig-
nificantly lower dose (∼ 1 Gy) with Reg 2.5 compared to
DJDC 5.0, but not to Reg 5.0.Figure 3 Whole Abdominal Irradiation: Dose distributions for Reg 2.5
DJDC 5.0 (Dynamic Jaw/Dynamic Couch delivery with a 5.0 cm maxim
penumbra in DJDC 5, for example in the left lobe of the liver (dark arrowh
arrowheads).The lungs, however, being the dose-limiting organs,
received very similar mean doses of about 8 Gy in all
modalities.
Discussion
This study is the first to show the characteristics of dy-
namic HT delivery for very large treatment volumes. In
all three settings investigated we saw, as expected, a sub-
stantial reduction of up to 55% in treatment time when
using 5 cm field width instead of 2.5 cm. As a result,
plans with Reg 5.0 showed an increased integral dose(“regular” delivery with a 2.5 cm field width; upper row) and
um field width; lower row). Note the slightly worse lateral dose
ead) and the increased incidence of hotspots in DJCD (light
Figure 4 Total Marrow Irradiation: Dose distributions for Reg 2.5 (“regular” delivery with a 2.5 cm field width; upper half) and DJDC
5.0 (Dynamic Jaw/Dynamic Couch delivery with a 5.0 cm maximum field width; lower half). Note the equivalent lung sparing in both
modalities (light arrowheads), which is accompanied by a more severe dose fall-off in the thoracic wall in DJDC 5.0. The dark arrowheads indicate
areas of higher dose exposure in DJDC 5.0 that form the correlate for the non-significantly increased integral dose in DJDC 5.0.
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ger field width. This effect could be abolished with the
use of DJDC delivery which produced fast treatment
plans with a sharp craniocaudal dose-falloff. Aside from
economic advantages based on a higher patient through-
put, shorter treatments primarily increase patient com-
fort and treatment safety by lowering the risk of
intrafractional movement. While treatment time reduc-
tion is attractive in every clinical setting, this feature is
particularly important for the treatment for very large
volumes: For a small target with 1.5 min treatment time,
a 50% increase in speed is a small gain compared to thetime needed for setup and image guidance. However,
speeding up beam-on-time from 30 min to 15 min for
large targets constitutes a substantial benefit.
Hemithoracic irradiation
For patients with Malignant Pleural Mesothelioma, trimo-
dal treatment with extensive surgery including resection
of the lung, the visceral and parietal pleura, the pericar-
dium and the diaphragm (extrapleural pneumonectomy,
EPP) followed by adjuvant radiotherapy and chemother-
apy is a radical treatment approach [11]. The radiooncolo-
gical target volume consists of the whole former pleural
Figure 5 Hemithoracic Irradiation: DJDC 5.0 (C; Dynamic Jaw/Dynamic Couch delivery with a 5.0 cm maximum field width)
plans resulted in a reduced dose penumbra compared to Reg 2.5 (A; (“regular” delivery with a 2.5 cm field width) and Reg 5.0
(“regular” delivery with a 5.0 cm field width).
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the contralateral lung, the heart, the liver, the small bowel
and the kidney. As pointed out by Allen et al. [12],
patients after EPP are more susceptible to lung toxicity
than patients without surgery. In a series of 13 patients, 6
developed fatal pneumonitis after fixed-beam IMRT treat-
ment with a mean lung exposure of 15 Gy. HT shows
dosimetric advantages over fixed-beam IMRT in terms of
dose homogeneity and target coverage as well as OAR
sparing. Mean dose to the contralateral lung can be low-
ered beyond 5 Gy with current HT with 2.5 cm field width
[1]. The use of a bigger field width to spare treatment time
has not proven clinically feasible because of a large dose
penumbra to the neck and the upper abdomen, most not-
ably the liver for right-sided mesothelioma (see Figure 5).
Yet, with DJDC technique, the present study could
demonstrate similar dose distributions to “regular” HT.
With DJDC 5.0, a drastic reduction of 55% in treatment
time could be realised. Considering a treatment schedule
of 27 fractions, this would translate into a total reduc-
tion of beam-on-time of 2 h 36 min.Figure 6 Whole Abdominal Irradiation: Vaginal sparing was better wi
cm maximum field width) compared to Reg 2.5 (A; (“regular” delivery
5.0 cm field width) due to a smaller dose penumbra.Volumetric modulated arc therapy promises very fast
IMRT treatments. In the case of 54 Gy hemithoracic
irradiation, when comparing fixed-beam IMRT plans to
RapidArcW (RA) plans, Scorsetti et al. [13] found equiva-
lent coverage and comparable OAR sparing, while treat-
ment time (from loading of the data to the end of delivery,
but excluding time for imaging and patient positioning)
was significantly lower for RA (3.7 min vs. 13.4 min). Dir-
ect comparison of different planning studies is prone to
misinterpretations due to different CTV definitions and
OAR contouring; however, compared to our DJDC data,
Scorsetti et al. achieved a faster treatment with RA (average
5:10 min vs. 3:42 min, DJDC vs. RA) with comparable dose
conformity and sparing of the contralateral lung and kid-
ney. A comparison of liver exposure is impossible as our
planning study included more patients with right-sided dis-
ease. Target coverage (TV95% 96,7% vs. 93.5, DJDC vs. RA)
and sparing of the ipsilateral kidney (mean dose 8.4 Gy vs.
12.9 Gy, DJDC vs. RA) were better in the DJDC plans.
When discussing the technical advances in hemithor-
acic irradiation after EPP, however, one has to take intoth DJDC 5.0 (C; Dynamic Jaw/Dynamic Couch delivery with a 5.0
with a 2.5 cm field width) and Reg 5.0 (“regular” delivery with a
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paring chemotherapy alone to trimodal treatment in-
cluding EPP in 50 patients. While acute and late
radiotherapy side effects in the EPP group were low with
only two cases of grade 3 pneumonitis, 1-year overall
survival was 52.2% in the EPP group compared to 73.1%
in the no EPP group. Among the 16 patients that com-
pleted surgery, 4 perioperative deaths occurred. After
adjustment for prognostic factors, the hazard ratio for
overall survival between the EPP and no EPP group was
2.75. The authors conclude that EPP in a trimodal set-
ting is associated with high morbidity and offers no
benefit. Consequentially, EPP has been abandoned in
many centers. Even so, the data presented in this study
can be applied to other clinical situations such as lung
cancer recurrence in the pleural cavity after pneumonec-
tomy or soft tissue sarcoma of the pleural cavity as well.Whole abdominal irradiation
Patients with advanced-stage ovarian cancer face a high
risk of recurrence in the peritoneal cavity even after
maximum cytoreductive surgery and adjuvant chemo-
therapy, while the risk of metastatic disease outside the
abdomen is relatively low [15]. With a 5-year survival
rate for patients with FIGO stage III ovarian cancer of
20-25%, long-term prognosis is poor. The integration of
Whole Abdominal Irradiation (WAI) into a multimodal
consolidation concept has been evaluated with contra-
dictory results, mainly because of high toxicity rates
leading to delayed or incomplete radiotherapy [16]. With
conventional radiotherapy techniques, delivery of ad-
equate doses to the upper abdomen is impossible due to
hepatic and renal toxicity [17]. The introduction of
IMRT into clinical routine has opened new possibilities
for a less toxic WAI as shown in a phase I trial [2] which
might help to increase the locoregional control of locally
advanced ovarian cancer. A phase I/II trial using HT is
currently recruiting in our department [18].
With Reg 2.5, one WAI treatment fraction of 1.5 Gy
takes about 18 minutes. Should WAI be integrated in
routine treatment regimes for ovarian cancer, treatment
acceleration will become an important issue. Using Reg
5.0 caused a significant drop in target coverage due to
the larger field width. DJDC 5.0 plans also showed a sig-
nificantly, but not as pronounced, loss in coverage. The
dynamic jaw component could partly compensate the
negative effect of the larger field width. In contrast,
DJDC could not counterbalance the higher liver expos-
ure caused by 5.0 cm jaw opening, probably because the
gradient to the liver lies more in diagonal direction than
in craniocaudal direction. Yet, liver exposure was only
increased by about 6% which we believe is not clinically
relevant.Mahantshetty et al. [19] compared WAI with fixed-
beam IMRT to RA with three arcs and two isocenters,
using 6 MV and 15 MV for both techniques and pre-
scribing 25 Gy to the whole abdomen and a simultan-
eous integrated boost of 45 Gy to the pelvis. They found
comparable target coverage and slightly improved homo-
geneity for RA. In terms of OAR sparing, 15 MV plans
were superior to lower energy plans; 15 MV IMRT and
15 MV RA showed a basic equivalence. Average treatment
time was significantly lower for RA (4:8 min for 6 MV and
15 MV RA vs. 18:0 min for 6 MV IMRT and 17:4 min
for 15 MV IMRT). As dose prescription differs strongly
from our plans, a reliable comparison to our data is diffi-
cult. When scaling down our PTV dose to 25 Gy, DJDC
would yield a superior liver sparing (mean dose 19.8 Gy vs.
22.4 Gy, DJDC vs. RA).
Total marrow irradiation
As part of the conditioning regimen before autologuous
stem cell transplantation, Total Body Irradiation (TBI)
plays a role in the treatment of a broad range of
hematological malignancies such as acute lymphoblastic
leukemia [20]. However, in the conditioning regimens of
other diseases such as Multiple Myeloma, TBI has been
abandoned due to extensive toxicity, particularly muco-
sitis, dependence on i.v. nutrition and hospitalisation
time [21,22]. The standard TBI technique uses large ap/pa
and lateral fields while blocking the lungs and an elec-
tron boost to the thoracic wall and is associated with
substantial toxicity. While restriction of the target
volume to the bone marrow with conventional techni-
ques is still associated with substantial toxicity [23],
modern IMRT techniques promise a further reduction
of OAR exposure [24]. Technical and clinical feasibility
of Total Marrow Irradiation (TMI) using HT have been
demonstrated by Wong et al. in 2006 [25]. In a phase I
dose escalation trial, TMI was investigated as part of a
tandem autologuous stem cell transplantation regimen
for patients with Multiple Myeloma. Dose-limiting tox-
icity was determined at 18 Gy. Up to a total dose of
16 Gy, TMI was tolerated well with a low incidence of
grade 3 nonhematological toxicities [26]. One major
drawback of advanced TMI techniques are, however,
the long treatment times required for highly conformal
dose delivery. For state-of-the art HT, treatment times
of 20–40 min are reported, depending on the chosen
field width [27].
For technical reasons, the maximum target length for
HT is limited to 160 cm. Like most other groups using
HT for TMI, we would address this problem by treating
the lower extremities with ap/pa fields on a linear
accelerator.
In the present study, Reg 2.5, Reg 5.0 and DJDC 5.0
could deliver the same dose to the target. The lungs as
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12 Gy particularly in Reg 5.0 and DJDC 5.0 delivery,
which is probably due to the larger maximum field
width. This phenomenon can also be seen in the DVHs
published by Han et al. [27]. Regarding a prescribed dose
of 18 Gy, this appears to be an unacceptable underdo-
sage at first glance. However, this is the dose level the
patient would have received with conventional TBI to
the whole target. Thus, with both modalities, 99% of the
PTV received the conventional TBI dose or more, and
76% received 17.1 Gy or more.
Some OAR were exposed to a significantly higher
mean dose with DJDC 5.0 compared to Reg 2.5, in
particular the liver, the kidneys, the parotid glans and
the thyroid gland. As the Reg 5.0 plans showed no signifi-
cant dose increase in those organs, this might be an
effect of the dynamic component. Yet, OAR exposure
was raised by approximately 1 Gy which is probably
not clinically relevant.
Current HT is often criticised because of long treat-
ment times and challenged by volumetric arc modulated
techniques that promise faster treatments. Very recently,
Han et al. [27] showed in a plan comparison study for
TMI a reduction of average beam-on time from 1122
sec to 628 sec when using RA instead of HT with 5 cm
field width. In addition, mean OAR dose could be low-
ered significantly in some organs such as the brain, the
right kidney, the optic nerves and the thyroid gland.
However, mean dose to the intestines as well as D10
(dose covering 10% of the volume) for the intestines,
both lungs and the stomach were significantly higher in
RA plans. On high dose levels (D80), no difference in
lung exposure could be detected. In addition to beam-
on-time, time for isocenter setup is needed for each arc
field in RA technique. Thus, the authors estimate that
total treatment time for RA and HT would be compar-
able. Our results with an average treatment time of 1105
sec for TMI are in line with their data.
One feature of DJDC technique is its ability to dimin-
ish the craniocaudal dose penumbra and consecutively
the integral dose as demonstrated for nasopharyngeal
cancer [28]. Contrary to expectations, in the present
study, a significantly lower integral dose with DJDC as
compared to Reg 5.0 could only be demonstrated for
WAI. In all other settings, integral dose did not differ
significantly between Reg 2.5, Reg 5.0 and DJDC 5.0,
which is probably due to crucial differences in PTV
shape: For nasopharyngeal cancer, the relation of longi-
tudinal to lateral extension is much smaller than for the
large volumens investigated in this study, giving the size
of the longitudinal penumbra a bigger influence. In
addition, the main dose gradient in nasopharyngeal can-
cer treatment (i.e. towards the myelon) is situated more
or less on the same coronal plane. In contrast, thegradients in Hemithoracic Irradiation, WAI in TMI vary
in location and cross the coronal planes, e.g. along the
lower rim of the liver. In such a setting, the bigger max-
imum field width in DJDC causes a bigger lateral dose
penumbra and outweighs the gain achieved by the
reduced craniocaudal penumbra.
Conclusions
The HT treatment of large volumes such as the hemi-
thorax, the abdominal cavity or the complete bone mar-
row can be sped up substantially by DJDC, while
maintaining excellent target coverage, OAR sparing and
sharp dose gradients above and below the target. Espe-
cially in the case of targets with very large craniocaudal
extensions such as Total Marrow Irradiation, it constitu-
tes a convenient and safe treatment modality. However,
for the time being, dynamic HT is still under develop-
ment and not available for clinical routine yet.
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